Voleon Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Voleon Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1M	Sell	674,245 -126,415	-16%	-$2.39M	0.22%	101
2026 Q1	$17.4M	Sell	800,660 -79,293	-9%	-$1.53M	0.38%	53
2025 Q4	$18.9M	Buy	879,953 +378,811	+76%	+$7.98M	0.41%	44
2025 Q3	$9.66M	Buy	501,142 +490,595	+4,652%	+$8.75M	0.24%	85
2025 Q2	$180K	Buy	+10,547	New	+$450K	0.01%	463
2019 Q4	–	Sell	-25,000	Closed	-$1.88M	–	233
2019 Q3	$1.88M	Sell	25,000 -9,000	-26%	-$1.06M	0.15%	103
2019 Q2	$5.17M	Buy	+34,000	New	+$4.13M	0.3%	69

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Voleon Capital Management's SRPT Position: Q2 2026 in Review

Voleon Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 16% in Q2 2026, selling an estimated $2.39M and leaving 674,245 shares worth $12.1M. The position accounts for 0.22% of the portfolio, ranked #101.

Voleon Capital Management first reported a position in SRPT in Q2 2019 and has held it in 7 quarters since. The position peaked at $18.9M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Voleon Capital Management held 674,245 shares of Sarepta Therapeutics worth $12.1M as of Q2 2026.
Voleon Capital Management sold 126,415 Sarepta Therapeutics shares in Q2 2026, an estimated $2.39M.
Sarepta Therapeutics made up 0.22% of Voleon Capital Management's portfolio in Q2 2026, its #101 holding.
Voleon Capital Management first reported a position in Sarepta Therapeutics in Q2 2019 and has held it in 7 quarters since.
Voleon Capital Management's Sarepta Therapeutics position peaked at $18.9M in Q4 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.